Methods of treatment using eszopiclone

Details for Australian Patent Application No. 2011202540 (hide)

Owner Sunovion Pharmaceuticals Inc.

Inventors Wessel, Thomas; Caron, Judy

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2011202540

Parent 2005231490

Filing date 31 May 2011

Wipo publication date 23 June 2011

International Classifications

A61K 31/4985 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Event Publications

16 June 2011 Complete Application Filed

23 June 2011 Application Open to Public Inspection

  Published as AU-A-2011202540

22 December 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

12 April 2012 Section 223 Application Received

  Sunovion Pharmaceuticals Inc. An application to extend the time from 08 Dec 2011 to 08 Apr 2012 in which to request examination has been filed . Address for service in Australia - Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000 Extensions of Time, Section 223

31 May 2012 Section 223 Application Allowed

  Sunovion Pharmaceuticals Inc. The time in which to request examination has been extended to 08 Apr 2012. Address for service in Australia - Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000 2012

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011202541-Cord Guide Element

2011202539-Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside